ALTACE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Altace, and when can generic versions of Altace launch?
Altace is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs.
The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the ramipril profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Altace
A generic version of ALTACE was approved as ramipril by WATSON LABS on October 24th, 2005.
Summary for ALTACE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 93 |
| Clinical Trials: | 26 |
| Patent Applications: | 4,705 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ALTACE |
| Drug Sales Revenues: | Drug sales revenues for ALTACE |
| What excipients (inactive ingredients) are in ALTACE? | ALTACE excipients list |
| DailyMed Link: | ALTACE at DailyMed |
Recent Clinical Trials for ALTACE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
| Ferrer Internacional S.A. | Phase 2 |
| University of Nebraska | Phase 4 |
Pharmacology for ALTACE
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ALTACE
US Patents and Regulatory Information for ALTACE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-003 | Feb 27, 2007 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-004 | Jan 28, 1991 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALTACE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-003 | Feb 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-003 | Feb 27, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-003 | Jan 28, 1991 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALTACE
See the table below for patents covering ALTACE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20020040795 | ⤷ Try a Trial | |
| Denmark | 140886 | ⤷ Try a Trial | |
| South Africa | 200201470 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events. | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ALTACE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0079022 | SPC/GB93/145 | United Kingdom | ⤷ Try a Trial | SPC/GB93/145, EXPIRES: 20040109 |
| 0265685 | SPC/GB98/047 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825 |
| 0265685 | 99C0001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
